Tumor Biology and Microenvironment Program Themes

Theme 1: To identify molecular, cellular determinants of malignancy (metastasis drivers)

Our investigators study key signaling pathways involved in tumorigenicity, tumor cell phenotypical plasticity, and tumor cell drug response (metastasis operatives).

Theme 1 Accomplishments 

Theme 2: To identify and exploit the underlying mechanisms of tumor metastasis (operatives)

Our investigators study the function and underlying mechanisms such as the extracellular proteolysis/signaling network that enable tumor cells to adapt to and eventually overcome the varying microenvironments.

Theme 2 Accomplishments 

Theme 3: To identify and exploit stromal reactivity and host immunity to tumor progression (host response to metastatic tumors)

Our investigators study the interaction of tumor cells with mesenchyme and innate immune cells. We also identify, evaluate and utilize adaptive cellular and humoral immune responses to develop immunotherapy approaches.

Theme 3 Accomplishments 

The Latest From Karmanos Cancer Institute

News

Karmanos Cancer Institute Recognizes Sarcoma Awareness Month

The Barbara Ann Karmanos Cancer Institute, cancer centers, and other organizations nationwide recognize July as Sarcoma Awareness Month. Sarcomas ...

Read More

'A Third Chance at Life': How a Growing Melanoma Led a West Michigan Woman to Karmanos for an Exclusive Clinical Trial

“My husband and I talked about it and decided that even if it didn’t save me, if it could help someone else, I had to do it.”   It was a warm...

Read More

Karmanos Case Manager Receives National Award for Excellence in Hematology-Oncology Social Work

The Leukemia & Lymphoma Society (LLS) has honored Cheryl Grey, LMSW, social worker and care manager at the Barbara Ann Karmanos Cancer Institu...

Read More
News

105.9 KISS FM | Getting a Second Opinion at Karmanos

Listen Now

WJR | Karmanos Cancer Institute Continues Its Community Education Series

Listen Now

WXYT 97.1 The Ticket | ‘Get a Mammogram’

Listen Now